Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY
University of Ulm
University of Ulm
University of Washington
Mayo Clinic
Mayo Clinic
Celldex Therapeutics
Mayo Clinic
Ohio State University Comprehensive Cancer Center